Tourmaline Bio Inc. (TRML) - Total Liabilities
Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has total liabilities worth $10.10 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TRML cash flow conversion to assess how effectively this company generates cash.
Tourmaline Bio Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Tourmaline Bio Inc. (TRML) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Tourmaline Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Tourmaline Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Treehouse Foods Inc
NYSE:THS
|
USA | $2.51 Billion |
|
Biotage AB
ST:BIOT
|
Sweden | Skr862.00 Million |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
China | CN¥8.92 Billion |
|
GMP Property SOCIMI SA
MC:YGMP
|
Spain | €1.02 Billion |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
Mexico | MX$21.86 Billion |
|
Actions Technology Co Ltd
SHG:688049
|
China | CN¥333.21 Million |
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
Germany | €865.11 Billion |
|
SAMPYO Cement Co. Ltd
KQ:038500
|
Korea | ₩660.87 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Tourmaline Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TRML market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tourmaline Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual total liabilities of Tourmaline Bio Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.95 Million | +70.36% |
| 2023-12-31 | $5.25 Million | -81.78% |
| 2022-12-31 | $28.83 Million | +234.73% |
| 2021-12-31 | $8.61 Million | +80.45% |
| 2020-12-31 | $4.77 Million | +102.76% |
| 2019-12-31 | $2.35 Million | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more